Clinical trial / 2015
In Crohn's disease patients in remission, 2000 IU/day vitamin D for 3 months maintained intestinal permeability and increased cathelicidin levels.
Twenty-seven Crohn's disease patients in remission were assigned to 2000 IU/day vitamin D or placebo for 3 months. At 3 months, 25(OH)D levels were significantly higher in the treated group (p < 0.001), with increased LL-37 concentrations (p = 0.050) and maintenance of intestinal permeability, whereas placebo patients experienced increases in small bowel (p = 0.018) and gastro-duodenal permeability (p = 0.030). Patients reaching 25(OH)D ≥ 75 nmol/L at 3 months had significantly lower CRP (p = 0.019), higher Quality of Life (p = 0.037), and higher LL-37 concentrations (p < 0.001) compared to those with levels < 75 nmol/L.
- Study type
- Double-blind randomised placebo-controlled study
- Who was studied
- 27 Crohn's disease patients in remission
- What was measured
- Intestinal permeability, cathelicidin (LL-37), hBD2, CDAI, CRP, fecal calprotectin, Quality of Life, and serum 25(OH)D
THE PAPER
Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study.
Raftery T, Martineau AR, Greiller CL, Ghosh S, McNamara D, Bennett K, Meddings J, O'Sullivan M. United European Gastroenterol J, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.